Format

Send to

Choose Destination
Tijdschr Psychiatr. 2010;52(9):615-25.

[Dose-escalation of SSRIS in major depressive disorder. Should not be recommended in current guidelines].

[Article in Dutch]

Author information

1
Universiteit van Amsterdam, Amsterdam. H.G.Ruthe@amc.uva.nl

Abstract

BACKGROUND:

In cases where patients with unipolar depression do not respond to a standard dose of selective serotonin reuptake inhibitors (SSRIS), treatment guidelines often recommend a higher dose. A systematic review of the literature revealed uncertainty about the efficacy of dose escalation and pointed to methodological weaknesses in earlier research.

AIM:

To review current practice and results concerning dose-escalation of SSRIS.

METHOD:

We made a summary of previously published English articles that systematically reviewed previous SSRI-dose-escalation studies in depressed patients and present the results of a recent double-blind randomised dose-escalation study of paroxetine. By means of a 123I-β-cit-spect study in a subgroup of the patients in the recent dose-escalation study it was possible to measure the amount of paroxetine bound to serotonin transporters. This provided combined clinical and pharmacological outcomes.

RESULTS:

The study with paroxetine provided clinical evidence that dose-escalation of paroxetine in depression was not effective and that adverse effects increased. The occupancy of the serotonin-transporters did not increase significantly after dose-escalation, despite increases in paroxetine serum levels.

CONCLUSION:

Dose-escalation of ssris for patients with unipolar depression who did not respond to a standard dose, does not improve response or the chance of remission. The pharmacological explanation for this is that the occupancy of the serotonin-transporters does not increase following dose-escalation.

PMID:
20862644
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Tijdschrift voor Psychiatrie
Loading ...
Support Center